Keytruda can be a brand (trade) name for pembrolizumab. It can be given by intravenous infusion every three to six weeks. Hardly ever, the usage of Keytruda results from the immune system attacking wholesome tissues and this can cause severe side effects for example pneumonitis, colitis, or hepatitis. In a lot of people, the use of Keytruda has res